Top Sites>Welcome to J&J Medical Connect

User-agent: * 
Disallow: /media/attestation/medinfohtmlimages/
Disallow: /media/attestation/general/
Disallow: /media/attestation/*general/
Disallow: /media/attestation/documents/
Disallow: /media/attestation/*documents/
Disallow: /media/attestation/idtlimages/
Disallow: /media/attestation/jsimages/
Disallow: /media/attestation/medinfohtmlimages/
Disallow: /404
Disallow: /custom-error-page
Disallow: /restricted
Disallow: /maintenance
Disallow: *q=
Disallow: *success=
Disallow: /Data/
Disallow: /*Data/
Disallow: /data/
Disallow: /*data/
Disallow: /Settings/
Disallow: /*Settings/
Disallow: /settings/
Disallow: /*settings/
Disallow: /sitecore/*
Sitemap: https://www.jnjmedicalconnect.com/sitemap.xml

# J&J MedicalConnect

> J&J Medical Connect is the site to access current scientific information about J&J Innovative Medicine products, offering support through live chat, email, video, and other communication channels.

## Documentation

- [AKEEGA - Dosage and Administration](https://www.jnjmedicalconnect.com/products/akeega/medical-content/dosage-administration): Dosage and administration information for AKEEGA® (niraparib and abiraterone acetate).
- [AKEEGA - Dosage Modifications](https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-dosage-modifications): Dosage and administration information for AKEEGA® (niraparib and abiraterone acetate) regarding dose modifications.
- [AKEEGA - Mechanism of Action](https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-mechanism-of-action): A summary of the mechanism of action of AKEEGA® (niraparib and abiraterone acetate).
- [CAPLYTA® (lumateperone)](https://www.jnjmedicalconnect.com/products/caplyta): This site provides access to current scientific information about CAPLYTA® (lumateperone).
- [CONCERTA - Dosing - Dosage and Administration](https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-dosing-dosage-and-administration.pdf): CONCERTA (methylphenidate HCl extended-release [MPH ER]) tablets should be administered orally once daily in the morning with or without food. CONCERTA tablets must be swallowed whole with the aid of liquids and must not be chewed, divided, or crushed.
- [CONCERTA - Pharmacokinetics of CONCERTA](https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-pharmacokinetics-of-concerta.pdf): CONCERTA (methylphenidate HCl extended-release [MPH ER]) is an osmotic controlled-release delivery system that allows once-daily dosing of methylphenidate (MPH).
- [Congress Materials - European Hematology Association (EHA 2024)](https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/eha-2024): Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at European Hematology Association.
- [Congress Materials – American Academy of Neurology (AAN 2025)](https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/aan-2025): Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at American Academy of Neurology.
- [Congress Materials – Digestive Disease Week (DDW 2025)](https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ddw-2025): Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at Digestive Disease Week.
- [Congress Materials – European Chron's and Colitis Organization (ECCO 2025)](https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ecco-2025): Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at European Chron's and Colitis Organization.
- [DARZALEX + DARZALEX FASPRO - Mechanism of Action](https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-mechanism-of-action): A summary of the mechanism of action of DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase).
- [DARZALEX + DARZALEX FASPRO - Use of Montelukast as a Pre-/Post-Medication](https://www.jnjmedicalconnect.com/products/darzalex/medical-content/montelukast-medication): A summary of the use of montelukast as a pre- or post-medication for DARZALEX® (daratumumab) infusion and DARZALEX FASPRO® (daratumumab and hyaluronidase) injection.
- [Does OPSYNVI Contain Lactose?](https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/does-opsynvi-contain-lactose): A summary of data regarding the lactose content of OPSYNVI® (macitentan and tadalafil).
- [Drug Interactions of REMICADE](https://www.jnjmedicalconnect.com/products/remicade/medical-content/drug-interactions-of-remicade): Drug interactions.
- [ERLEADA - What are the Possible Side Effects of ERLEADA?](https://www.jnjmedicalconnect.com/products/erleada/medical-content/what-are-the-possible-side-effects-of-erleada): Information on possible side effects of ERLEADA®, including heart disease, stroke or mini-stroke, fractures and falls, seizure, severe skin reactions, and lung problems.
- [ERLEADA – TITAN study](https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-titan-study01): A summary of clinical data from the TITAN study of ERLEADA® (apalutamide).
- [High-risk Smoldering Multiple Myeloma](https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/high-risk-smoldering-multiple-myeloma): This smoldering multiple myeloma (SMM) educational page includes diagnostic criteria, risk of progression, risk stratification, and management considerations.
- [How Does OPSYNVI Work?](https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/how-does-opsynvi-work): A summary of data regarding how OPSYNVI® (macitentan and tadalafil) works.
- [How Long Does It Take for INVEGA SUSTENNA to be Removed from Your Body?](https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/how-long-does-it-take-for-invega-sustenna-to-be-removed-from-your-body-1): A summary of data regarding the length of time INVEGA SUSTENNA® (paliperidone palmitate 1-month) remains in the body.
- [How Should I Store OPSYNVI?](https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/how-should-i-store-opsynvi): A summary of data regarding the storage of OPSYNVI® (macitentan and tadalafil).
- [Interactive Ingredient Checker](https://www.jnjmedicalconnect.com/resources/interactive-ingredient-checker): Interactive Ingredient Checker provides information regarding the presence or absence of specific ingredients (e.g., latex, glucose, animal-derived) and/or allergens in select Johnson & Johnson products.
- [Johnson & Johnson REMS](https://www.jnjmedicalconnect.com/resources/rems): Risk evaluation and mitigation strategies (REMS).
- [Mechanism of Action of SPRAVATO](https://www.jnjmedicalconnect.com/products/spravato/medical-content/mechanism-of-action-of-spravato): A summary of the mechanism of action of SPRAVATO® (esketamine).
- [Presentation: Talquetamab + Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1b Results From RedirecTT-1 With >1 Year of Follow-Up](https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/talquetamab-tal-teclistamab-tec-in-patients-pts-with-relapsedrefractory-multiple-myeloma-rrmm-update.pdf): Tal + tec combination therapy showed side effects similar to each drug on its own. Infections were common, but serious new infections dropped after 6 months, and the chosen treatment dose was as safe as the other doses tested.
- [SIMPONI ARIA® (golimumab)](https://www.jnjmedicalconnect.com/products/simponi-aria): This site provides access to current scientific information about SIMPONI ARIA® (golimumab).
- [SPRAVATO - Urine Drug Screen](https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-urine-drug-screen): A summary of clinical data on urine drug screening and SPRAVATO® (esketamine) nasal spray.
- [TOPAMAX - Dosing - Discontinuation or Withdrawal of Therapy](https://www.jnjmedicalconnect.com/media/attestation/products/topamax/topamax-dosing-discontinuation-or-withdrawal-of-therapy.pdf): In patients with or without a history of seizures or epilepsy, antiepileptic drugs, including TOPAMAX®, should be gradually withdrawn to minimize the potential for seizures or increased seizure frequency.
- [TREMFYA - Mechanism of Action and Molecular Profile](https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-mechanism-of-action-and-molecular-profile): A summary of information on in vitro binding affinity and cellular potency of the antigen recognition domains of TREMFYA® (guselkumab).
- [TREMFYA - Occurrence of Gastrointestinal Serious Adverse Events in Adult Patients with Plaque Psoriasis or Psoriatic Arthritis](https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-gastrointestinal-serious-adverse-events-in-adult-patients-with-plaque-psorias): A summary of the clinical data regarding the occurrence of gastrointestinal serious adverse events with TREMFYA® (guselkumab) use in adult patients with PsO/PsA.
- [TREMFYA - What Are the Possible Side Effects of TREMFYA?](https://www.jnjmedicalconnect.com/products/tremfya/medical-content/what-are-the-possible-side-effects-of-tremfya): TREMFYA may cause serious side effects, including serious allergic reactions, infections, and liver problems.
- [Welcome to J&J Medical Connect](https://www.jnjmedicalconnect.com/): J&J Medical Connect is the site to access current scientific information about J&J Innovative Medicine products, offering support through live chat, email, video, and other communication channels.
- [What are the Possible Side Effects of INVEGA SUSTENNA?](https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/what-are-the-possible-side-effects-of-invega-sustenna): A summary of safety data regarding the potential side effects of INVEGA SUSTENNA® (paliperidone palmitate 1-month).
- [What Are the Possible Side Effects of REMICADE?](https://www.jnjmedicalconnect.com/products/remicade/medical-content/what-are-the-possible-side-effects-of-remicade): A summary of safety data regarding the potential side effects of REMICADE® (infliximab).
- [What are the Possible Side Effects of RISPERDAL?](https://www.jnjmedicalconnect.com/products/risperdal/medical-content/what-are-the-possible-side-effects-of-risperdal): A summary of safety data regarding the potential side effects of RISPERDAL® (risperidone).
- [What are the Possible Side Effects of RISPERDAL?](https://www.jnjmedicalconnect.com/products/risperdal/medical-content/what-are-the-possible-side-effects-of-risperdal): A summary of safety data regarding the potential side effects of RISPERDAL® (risperidone).
- [What are the Possible Side Effects of SPRAVATO?](https://www.jnjmedicalconnect.com/products/spravato/medical-content/what-are-the-possible-side-effects-of-spravato): A summary of data regarding the potential side effects of SPRAVATO® (esketamine).
- [What is XARELTO?](https://www.jnjmedicalconnect.com/products/xarelto/medical-content/what-is-xarelto): A summary of what XARELTO® (rivaroxaban) is used for.
- [Why is there a Risk Evaluation and Mitigation Strategy (REMS) Program with SPRAVATO?](https://www.jnjmedicalconnect.com/products/spravato/medical-content/why-is-there-a-risk-evaluation-and-mitigation-strategy-rems-program-with-spravato): A summary of data regarding the Risk Evaluation and Mitigation Strategy (REMS) program for SPRAVATO® (esketamine).
- [XARELTO - How Supplied](https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-how-supplied): Information on how XARELTO® (rivaroxaban) is supplied.
- [XARELTO - Mechanism of Action](https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-mechanism-of-action): A summary of the mechanism of action of XARELTO® (rivaroxaban).